|
US2021122750A1
|
|
Gpr183 antagonists for the treatment of pain
|
|
US2021024489A1
|
|
Treatment and prevention of neuropathic pain with p2y14 antagonists
|
|
US2020372643A1
|
|
Digital telepathology and virtual control of a microscope using edge computing
|
|
WO2020236777A1
|
|
Reprogramming of lipid metabolism to inhibit t cell senescence and enhance tumor immunotherapy
|
|
WO2020227180A1
|
|
Sulfur and amide tropolone inhibitors of nucleotidyl transferases and uses therefor
|
|
US2020346183A1
|
|
Visible light induced photogeneration of ground state atomic oxygen
|
|
WO2020210598A1
|
|
Systems and methods for guiding surgical tools
|
|
WO2020176544A1
|
|
Treatment of alzheimer's disease
|
|
US2020262808A1
|
|
Dibenzothiophene compounds
|
|
WO2020168274A1
|
|
Treatment of chronic headaches
|
|
WO2020132004A1
|
|
Bet inhibitors for modulating dux4 expression in fshd
|
|
WO2020106773A1
|
|
Treatment of irritable bowel syndrome
|
|
WO2020102737A1
|
|
Isotope labeling for universal multiplexing of metabolites
|
|
WO2020092193A1
|
|
Treatments for zika virus infection
|
|
WO2020086927A1
|
|
Peptides for inducing heterosubtypic influenza t cell responses
|
|
US2020032229A1
|
|
Reduced immunogenic proteins for lysosomal storage disorders
|
|
WO2020061211A1
|
|
Use of highly-selective adenosine 3a receptor subtype agonists
|
|
WO2020009889A1
|
|
ALPHAvBETA1 INTEGRIN ANTAGONISTS
|
|
WO2019236603A1
|
|
Methods and compositions for treating decreased cognitive ability
|
|
US2020018705A1
|
|
Fluorescent probes for drug permeability in gram negative bacteria
|
